Your browser doesn't support javascript.
loading
Multicentre validation of CT grey-level co-occurrence matrix features for overall survival in primary oesophageal adenocarcinoma.
O'Shea, Robert; Withey, Samuel J; Owczarczyk, Kasia; Rookyard, Christopher; Gossage, James; Godfrey, Edmund; Jobling, Craig; Parsons, Simon L; Skipworth, Richard J E; Goh, Vicky.
Afiliación
  • O'Shea R; Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
  • Withey SJ; Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
  • Owczarczyk K; Department of Radiology, Royal Marsden Hospital NHS Trust, Sutton, Surrey, UK.
  • Rookyard C; Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
  • Gossage J; Department of Clinical Oncology, Guy's & St Thomas' Hospitals NHS Foundation Trust, London, UK.
  • Godfrey E; Department of Cancer Imaging, School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK.
  • Jobling C; Department of Surgery, Guy's & St Thomas' Hospitals NHS Foundation Trust, London, UK.
  • Parsons SL; Department of Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Skipworth RJE; Department of Radiology, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK.
  • Goh V; Department of Surgery, Nottingham University Hospitals NHS Foundation Trust, Nottingham, UK.
Eur Radiol ; 34(10): 6919-6928, 2024 Oct.
Article en En | MEDLINE | ID: mdl-38526750
ABSTRACT

BACKGROUND:

Personalising management of primary oesophageal adenocarcinoma requires better risk stratification. Lack of independent validation of proposed imaging biomarkers has hampered clinical translation. We aimed to prospectively validate previously identified prognostic grey-level co-occurrence matrix (GLCM) CT features for 3-year overall survival.

METHODS:

Following ethical approval, clinical and contrast-enhanced CT data were acquired from participants from five institutions. Data from three institutions were used for training and two for testing. Survival classifiers were modelled on prespecified variables ('Clinical' model age, clinical T-stage, clinical N-stage; 'ClinVol' model clinical features + CT tumour volume; 'ClinRad' model ClinVol features + GLCM_Correlation and GLCM_Contrast). To reflect current clinical practice, baseline stage was also modelled as a univariate predictor ('Stage'). Discrimination was assessed by area under the receiver operating curve (AUC) analysis; calibration by Brier scores; and clinical relevance by thresholding risk scores to achieve 90% sensitivity for 3-year mortality.

RESULTS:

A total of 162 participants were included (144 male; median 67 years [IQR 59, 72]; training, 95 participants; testing, 67 participants). Median survival was 998 days [IQR 486, 1594]. The ClinRad model yielded the greatest test discrimination (AUC, 0.68 [95% CI 0.54, 0.81]) that outperformed Stage (ΔAUC, 0.12 [95% CI 0.01, 0.23]; p = .04). The Clinical and ClinVol models yielded comparable test discrimination (AUC, 0.66 [95% CI 0.51, 0.80] vs. 0.65 [95% CI 0.50, 0.79]; p > .05). Test sensitivity of 90% was achieved by ClinRad and Stage models only.

CONCLUSIONS:

Compared to Stage, multivariable models of prespecified clinical and radiomic variables yielded improved prediction of 3-year overall survival. CLINICAL RELEVANCE STATEMENT Previously identified radiomic features are prognostic but may not substantially improve risk stratification on their own. KEY POINTS • Better risk stratification is needed in primary oesophageal cancer to personalise management. • Previously identified CT features-GLCM_Correlation and GLCM_Contrast-contain incremental prognostic information to age and clinical stage. • Compared to staging, multivariable clinicoradiomic models improve discrimination of 3-year overall survival.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Adenocarcinoma / Tomografía Computarizada por Rayos X Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur Radiol / Eur. radiol / European radiology Asunto de la revista: RADIOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Esofágicas / Adenocarcinoma / Tomografía Computarizada por Rayos X Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Eur Radiol / Eur. radiol / European radiology Asunto de la revista: RADIOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Alemania